All In Biotech

NDA 021618 · Mission Pharma

Tindamax

Tinidazole · Oral · Nitroimidazole Antimicrobial

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Dec 15, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

May 17, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

44

9 Phase 3, 2 recruiting

FAERS reports

435

314 serious, 20 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POTENTIAL RISK FOR CARCINOGENICITY WARNING: POTENTIAL RISK FOR CARCINOGENICITY Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent [see Nonclinical Toxicology (13.1)]. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Limit use of TINIDAZOLE to approved indications only [see Indications and Usage (1.1, 1.2, 1.3)] . Avoid chronic use [see Warnings and Precautions (5.1)]. WARNING: POTENTIAL RISK FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent (13.1). Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Limit use...

What it is approved for

From the label in effect Dec 1, 2025.

1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting...

Mechanism: Tinidazole is an antiprotozoal, antibacterial agent. [See Clinical Pharmacology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 21, 2007 Supplement 3 · Efficacy LabelLetter
  • May 17, 2004 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLetterLabel
2 products under this application
  • TINDAMAX · TINIDAZOLE 250MG · TABLET, ORAL · Prescription · TE AB
  • TINDAMAX · TINIDAZOLE 500MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tinidazole" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective33
  • nausea28
  • off label use26
  • pruritus26
  • headache25
  • diarrhoea22
  • vomiting22
  • pyrexia21
  • rash21
  • anxiety20
  • neuropathy peripheral19
  • paraesthesia19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20058
20063
20074
20085
200910
201011
201116
201218
201318
201425
201521
201631
201718
201827
201938
202049
202131
202224
202334
202412
202524
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 390 on PubMed

Sponsor: Mission Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.